Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.7796EUR
−47.24 MEUR
14.67 M
About Aptose Biosciences, Inc.
Sector
CEO
William G. Rice
Headquarters
Toronto
Website
Employees (FY)
35
Founded
1986
FIGI
BBG005Y2FMM7
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Aptos Biosciences APTO - Testing critical supportThis level should provide substantial support for a possible bounce. The risk/reward here is favorable for a long. Stop loss is essential, as always.
APTO Technical Analysis 🧙Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm
APTO Technical Analysis 🧙Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm
APTO Technical Analysis. 🧙Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm
See all ideas
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Aptose Biosciences Inc. stocks are traded under the ticker LTI.
We've gathered analysts' opinions on Aptose Biosciences Inc. future price: according to them, LTI price has a max estimate of 6.50 EUR and a min estimate of 4.64 EUR. Watch LTI chart and read a more detailed Aptose Biosciences Inc. stock forecast: see what analysts think of Aptose Biosciences Inc. and suggest that you do with its stocks.
Yes, you can track Aptose Biosciences Inc. financials in yearly and quarterly reports right on TradingView.
Aptose Biosciences Inc. is going to release the next earnings report on Aug 6, 2024. Keep track of upcoming events with our Earnings Calendar.
LTI earnings for the last quarter are −0.68 EUR per share, whereas the estimation was −1.02 EUR resulting in a 33.47% surprise. The estimated earnings for the next quarter are −0.53 EUR per share. See more details about Aptose Biosciences Inc. earnings.
Aptose Biosciences Inc. revenue for the last quarter amounts to 0 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
LTI net income for the last quarter is −8.89 M EUR, while the quarter before that showed −11.13 M EUR of net income which accounts for 20.09% change. Track more Aptose Biosciences Inc. financial stats to get the full picture.
No, LTI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 28, 2024, the company has 35.00 employees. See our rating of the largest employees — is Aptose Biosciences Inc. on this list?
Like other stocks, LTI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aptose Biosciences Inc. stock right from TradingView charts — choose your broker and connect to your account.